Cytokinetics CYTK Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's change in accrued liabilities?
- Cytokinetics (CYTK) reported change in accrued liabilities of -$6.21M in Q1 2026.
- How has Cytokinetics's change in accrued liabilities changed year-over-year?
- Cytokinetics's change in accrued liabilities increased by 56.8% year-over-year, from -$14.37M to -$6.21M.
- What is the long-term trend for Cytokinetics's change in accrued liabilities?
- Over 4 years (2021 to 2025), Cytokinetics's change in accrued liabilities has grown at a 22.2% compound annual growth rate (CAGR), from $15.06M to $33.6M.
- What does change in accrued liabilities mean?
- The net change in expenses recognized but not yet paid in cash.
- How do you interpret change in accrued liabilities?
- An increase acts as a source of cash flow by deferring actual payment of recognized expenses.
- How does change in accrued liabilities compare across companies?
- Standard operational metric for tracking short-term liability management.